Category hub · Women 40-55
Metabolic & GLP-1
Peptides involved in blood sugar, appetite, body composition, and weight, including the GLP-1 receptor agonists that have reshaped metabolic medicine. This category spans some of the best-studied peptides as well as more speculative ones, and we label each clearly.
Peptides in this category
16 profiles5-Amino-1MQ
NNMT enzyme inhibitor (small molecule)
5-Amino-1MQ is a small-molecule compound (not a peptide) that blocks an enzyme called NNMT, which has been linked to fat-tissue metabolism in animals. In mouse studies it was associated with reduced fat gain, but there is no published human data. It is a research chemical, and its effects and safety in people are unknown.
Read profileAOD-9604
Modified growth-hormone fragment (176-191)
AOD-9604 is a small fragment of human growth hormone that was investigated as a fat-loss agent. Early company-sponsored trials did not show meaningful weight loss beyond placebo, and it was not approved for that use. Today it is sold as a research chemical, and good human evidence for weight benefit is lacking.
Read profileAdipotide
Pro-apoptotic targeting peptide (prohibitin-targeting)
Adipotide is an experimental peptide that, in animals, targets the blood supply of fat tissue and triggers fat cells to die. In obese monkeys it produced weight loss, but it also raised safety concerns, including kidney effects. There are no established human trials supporting its use, and it is a research compound only.
Read profileCagrilintide
Long-acting amylin receptor agonist
Cagrilintide is an experimental long-acting medicine that mimics amylin, a hormone that works alongside insulin to reduce appetite and food intake. It is being studied for weight management, often combined with a GLP-1 drug, and human trials are ongoing. It is not approved, and long-term safety is not yet established.
Read profileCagrilintide + Semaglutide
Amylin agonist plus GLP-1 agonist combination
This is a combination of two appetite-acting medicines: cagrilintide (an amylin agonist) and semaglutide (a GLP-1 agonist). The idea is to target two different satiety pathways at once for greater weight loss. The combination has been studied in human trials with encouraging results, but it is not yet approved as a single product.
Read profileDulaglutide
GLP-1 receptor agonist
Dulaglutide is a once-weekly injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar. It is FDA-approved for type 2 diabetes, and large human trials support its effects on blood sugar and cardiovascular risk. It is prescription-only.
Read profileEloralintide
Amylin receptor agonist
Eloralintide is an experimental amylin receptor agonist being developed for weight management. It is at an early stage of clinical development, and little human data has been published so far. It is not approved, and its efficacy and safety in people are not yet established.
Read profileLiraglutide
GLP-1 receptor agonist
Liraglutide is a daily injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar and reduce appetite. It is FDA-approved for type 2 diabetes and for weight management, supported by large human trials. It is prescription-only.
Read profileMazdutide
Dual GLP-1 and glucagon receptor agonist
Mazdutide is an experimental medicine that activates two receptors (GLP-1 and glucagon) to lower blood sugar, reduce appetite, and increase energy use. It is in clinical development for weight management and diabetes, with trials concentrated in China. It is not approved, and long-term safety is not yet established.
Read profileOrforglipron
Oral non-peptide GLP-1 receptor agonist
Orforglipron is an experimental GLP-1 receptor agonist taken as a pill rather than an injection. Because it is a small molecule rather than a peptide, it does not require refrigeration or food restrictions like some oral peptides. Human trials have reported weight loss and blood-sugar benefits, but it is still in development and not approved.
Read profileSemaglutide
GLP-1 receptor agonist
Semaglutide is a medicine that mimics a gut hormone called GLP-1, which helps control blood sugar and appetite. It is FDA-approved for type 2 diabetes and for weight management, and large human trials show meaningful blood-sugar and weight reductions. It is prescription-only and is not a casual supplement.
Read profileSLU-PP-332
ERR (estrogen-related receptor) agonist (small molecule)
SLU-PP-332 is an experimental small-molecule compound (not a peptide) that activates estrogen-related receptors involved in cellular energy use. In mice it was associated with increased energy expenditure and effects resembling exercise, which is why it is sometimes called an "exercise mimetic." There is no human data, and its effects and safety in people are unknown.
Read profileRetatrutide
Triple GIP, GLP-1, and glucagon receptor agonist
Retatrutide is an experimental medicine that activates three hormone receptors at once (GIP, GLP-1, and glucagon), aiming to amplify weight loss and metabolic effects. Early to mid-stage human trials have reported large weight reductions, but it is still in development and not approved. Longer-term safety is not yet established.
Read profileSurvodutide
Dual GLP-1 and glucagon receptor agonist
Survodutide is an experimental medicine that activates two receptors (GLP-1 and glucagon) and is being studied for weight management and for liver disease (MASH). Human trials have reported weight loss and improvements in liver measures, but it is still in development and not approved. Long-term safety is not yet established.
Read profileTesofensine
Triple monoamine reuptake inhibitor
Tesofensine is an experimental small-molecule drug (not a peptide) that affects brain chemicals to reduce appetite. It was originally studied for neurological conditions, then for obesity, where mid-stage human trials reported weight loss. It is not FDA-approved, and its long-term safety, including cardiovascular and psychiatric effects, is not established.
Read profileTirzepatide
Dual GIP and GLP-1 receptor agonist
Tirzepatide is a medicine that activates two gut-hormone receptors at once (GIP and GLP-1), which together lower blood sugar and reduce appetite. It is FDA-approved for type 2 diabetes and for weight management, and large human trials show strong results. It is prescription-only.
Read profile